Table 2. Study characteristics of 8 studies of the association between statins use and prostate cancer-specific mortality.
| Study (year) | Country | Duration of follow-up (Mean ± SD) | All male subjects (%) | No. of died from PCa* | Estimate(s)(95% confidence interval, CI) |
|---|---|---|---|---|---|
| Serruys et al. (2002)30 | Multicenter | 3.9y | 1406 (83.8) | 4 | HR:0.98 (0.14–6.92) |
| Marcella et al. (2011)31 | US | NR | 760 (100.0) | 380 | HR:0.45 (0.29–0.71) |
| Nielsen et al. (2012)32 | Denmark | 2.6y | 27752 (100.0) | 10542 | HR:0.81 (0.75–0.88) |
| Grytli et al. (2013)33 | Norway | 39 M | 3699 (100.0) | NR | HR:0.78 (0.67–0.90) |
| Geybels et al. (2013)22 | US | 6.1y | 1001 (100.0) | 39 | HR:0.19 (0.06–0.56) |
| Margel et al. (2013)34 | Canada | 4.64y | 3837 (100.0) | 291 | HR:0.78 (0.62–0.99) |
| Yu et al. (2014)35 | UK | 4.4y ± 2.9 | 11772 (100.0) | 1791 | HR:0.76 (0.66–0.88) |
| Caon et al. (2014)36 | Canada | 8.4y | 3851 (100.0) | NR | HR:0.77 (0.55–1.08) |
*PCa, prostate cancer.